Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Forcasting the prevalence of myopia among students aged 6-18 years in China from 2021 to 2030].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2021
Same author

[Progress on the lifeomics studies of chronic obstr uctive pulmonary disease].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2019
Same author

[Rituximab for primary focal segmental glomerulosclerosis].

Zhonghua nei ke za zhi·2017
Same author

[Research advances in diabetic retinopathy telescreening systems].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2016
Same author

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Physical Activity and Sedentary Behaviour in Children With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Ten-year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor V deficiency: a concise review.

J N Huang1, M A Koerper

  • 1Department of Pediatrics, UCSF Children's Hospital, San Francisco, California 94143-0106, USA.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|January 15, 2009
PubMed
Summary
This summary is machine-generated.

Factor V (FV) deficiency, caused by gene mutations or acquired conditions, presents with bleeding symptoms. Treatment primarily involves fresh frozen plasma, with other options for complex cases.

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Jun 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Factor V (FV) is essential for thrombin generation, acting as a cofactor in the prothrombinase complex.
  • FV deficiency arises from genetic mutations or acquired factors, impacting its transport and function.
  • Low FV levels are also observed in platelet disorders and due to certain medications or medical conditions.

Purpose of the Study:

  • To summarize the causes, clinical manifestations, and management strategies for Factor V deficiency.
  • To provide an overview of the current understanding of FV's role in hemostasis.

Main Methods:

  • Literature review of Factor V deficiency, including genetic and acquired causes.
  • Analysis of clinical presentations, bleeding risks, and treatment outcomes.
  • Synthesis of information on therapeutic interventions and management of refractory cases.

Main Results:

  • FV deficiency stems from FV gene mutations or issues with FV transport, platelet granule disorders, or acquired conditions like topical thrombin use.
  • Clinical symptoms range from mucosal and postoperative bleeding to more severe hemorrhages, though generally less severe than hemophilia.
  • Fresh frozen plasma is the primary treatment, supplemented by antifibrinolytics, prothrombin complex concentrates, rFVIIa, and platelet transfusions in specific scenarios.

Conclusions:

  • Factor V deficiency has diverse etiologies and clinical impacts.
  • Management requires a tailored approach, with fresh frozen plasma as the cornerstone therapy.
  • Advanced treatments are available for complex or refractory cases, including those with inhibitors.